A Phase I Study of ZD6474 (Vandetanib) Concurrent With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase I Study of ZD6474 (Vandetanib) Concurrent With Whole Brain Radiotherapy for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer (NSCLC).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Brain metastases; Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 11 Jan 2011 Planned end date changed from 1 Apr 2012 to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 09 Dec 2010 Additional lead investigator identified as reported by ClinicalTrials.gov.
    • 09 Dec 2010 Planned end date changed from 1 Jun 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top